45 results on '"Betticher D"'
Search Results
2. NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma
3. The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)
4. Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients
5. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
6. Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03
7. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma
8. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL)
9. The use of Allelic Expression Differences to Ascertain Functional Polymorphisms Acting in cis: Analysis of MMP1 Transcripts in Normal Lung Tissue
10. Rituximab–EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study
11. Docetaxel für die neoadjuvanten Therapieansätze der frühen Stadien des nicht-kleinzelligen Bronchuskarzinoms
12. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study
13. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial
14. The effect of Rituximab on patients with follicular and mantle-cell lymphoma
15. The cyclin-dependent kinase inhibitors p18INK4c and p19INK4d are highly expressed in CD34+ progenitor and acute myeloid leukaemic cells but not in normal differentiated myeloid cells
16. Treatment of hairy cell leukemia with cladribine(2-chlorodeoxyadenosine) by subcutaneous bolus injection:a phase II study
17. Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenstrom's macroglobulinaemia
18. Rare case of remission of a patient with small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT) stage IV: Case report.
19. The Hyperreactive Malarial Splenomegaly Syndrome in a European: Has the Treatment a Modulatory Effect on the Immune System?
20. Two case reports of a malignant germ cell tumor of ovary and a granulosa cell tumor: interest of tumoral immunochemistry in the identification and management.
21. P30.01 Extended Resections for Advanced Stages T3/T4 NSCLC After Neoadjuvant Treatment: Conclusions of SAKK Pooled Analysis (16/96, 16/00, 16/01).
22. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study.
23. Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability.
24. The use of Allelic Expression Differences to Ascertain Functional Polymorphisms Acting incis: Analysis ofMMP1Transcripts in Normal Lung Tissue.
25. S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas.
26. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression.
27. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies.
28. Melanoma: chemotherapy.
29. Increased colony growth in peripheral blood cultures from patients with ALL depends on immunological subtype.
30. Abnormal expression of CCND1 and RB1 in resection margin epithelia of lung cancer patients.
31. High levels of loss at the 17p telomere suggest the close proximity of a tumour suppressor.
32. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer.
33. Dacarbazine and interferon-α 2a in advanced malignant melanoma.
34. 143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial.
35. Trimodality therapy for locally advanced non-small-cell lung cancer: a curative approach.
36. 9147 Bevacizumab and erlotinib as first-line therapy in advanced (stage IIIB/IV) non-squamous non-small-cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression – a multicenter phase II trial of SAKK.
37. 815 Elderly patients (pts) with unresectable localised or metastatic non-small-cell-lung-cancer (NSCLC): results of a phase II study with oral navelbineâ (nvb) given as a weekly monotherapy and first line treatment.
38. Echinocytic transformation and aggregation of red cells in uremic patients.
39. 1570P Outcome and prognostic factors of COVID-19 infection in cancer patients: Final results of SAKK 80/20.
40. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
41. 1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial.
42. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial
43. LBA80 Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA).
44. CN38 Implementing a nursing symptom self-management intervention: The Symptom Navi Program.
45. 1667PDImpact of early prophylactic cranial irradiation with hippocampal avoidance on neurocognitive function in patients with limited disease small cell lung cancer: A multicenter phase II trial (SAKK 15/12).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.